Pomerantz LLP Investigates Potential Securities Claims Against PepGen Inc.
NEW YORK, March 17, 2025
Pomerantz LLP, a leading securities law firm, is investigating potential securities claims on behalf of investors of PepGen Inc (“PepGen” or the “Company”) (NASDAQ: PEPG). The investigation concerns possible violations of the Securities Exchange Act of 1934 by PepGen and certain of its officers and directors.
Background
PepGen is a clinical-stage biotechnology company focused on developing therapies for genetic disorders using its proprietary mRNA technology. The Company’s lead product candidate, PepMiller-1, is a potential treatment for cystic fibrosis. PepGen’s stock price has experienced significant volatility in the past year, with a 52-week range of $1.50 to $12.00.
Alleged Misstatements and Omissions
The investigation focuses on certain statements made by PepGen regarding its clinical trials for PepMiller-1. Specifically, the firm is examining whether the Company misrepresented the safety and efficacy data from these trials, as well as the timing of regulatory submissions and potential commercialization.
Investor Contact Information
Investors who purchased or otherwise acquired PepGen securities between [specific dates] are encouraged to contact Pomerantz LLP for a consultation, including investors who may have sold shares short and held a short position at the relevant time. Investors interested in recovering their investment losses are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 167.
Impact on Individual Investors
If the investigation reveals that PepGen and its executives made materially false or misleading statements or failed to disclose material information, affected investors may be entitled to seek damages and other remedies. These remedies may include recovering their investment losses, as well as any damages or interest that may be available under the law.
Global Implications
- Heightened scrutiny of the biotech industry: This investigation may lead to increased regulatory and investor attention on the biotech sector, particularly companies with promising but unproven therapies.
- Impact on investor confidence: Negative news surrounding a biotech company can have a ripple effect, potentially causing other investors to reconsider their holdings in the sector.
- Implications for clinical trials: The investigation may raise questions about the reliability of clinical trial data and the role of regulatory agencies in ensuring the safety and efficacy of new therapies.
Conclusion
Pomerantz LLP’s investigation of potential securities claims against PepGen Inc highlights the importance of accurate and transparent communication from publicly traded companies, particularly those in the biotech sector. As the industry continues to evolve and push the boundaries of scientific innovation, investors must remain vigilant and demand transparency to protect their investments. If you believe you may have a claim, contact Pomerantz LLP for a consultation.
Investors should carefully consider the potential risks and uncertainties inherent in investing in biotechnology companies, particularly those with unproven therapies. As the investigation into PepGen unfolds, it is essential to stay informed and seek professional advice if necessary.
